Salix Pharmaceuticals DEFA14A Additional proxy soliciting materials

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

Filed by the Registrantx                            Filed by a Party other than the Registrant¨

Check the appropriate box:

¨ Preliminary Proxy Statement

¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

¨ Definitive Proxy Statement

x Definitive Additional Materials

¨ Soliciting Material Pursuant to § 240.14a-12

Salix Pharmaceuticals, Ltd.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

x No fee required.

¨ Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

¨ Fee paid previously with preliminary materials.

¨ Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

IMPORTANT ANNUAL STOCKHOLDERS’ MEETING

INFORMATION — YOUR VOTE COUNTS!

Important Notice Regarding the Availability of Proxy Materials for the

Annual Meeting of Stockholders of Salix Pharmaceuticals, Ltd.

To Be Held on June 18, 2009 at 9:00 a.m. Eastern Time

1700 Perimeter Park Drive, Morrisville, North Carolina

Under new Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual meeting of stockholders of Salix Pharmaceuticals, Ltd. are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy of the materials. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important!

This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The proxy statement, form of electronic proxy card, 2008 annual report to stockholders and annual report on Form 10-K as filed with the SEC are available at:

	Easy Online Access — A Convenient Way to View Proxy Materials and Vote
	When you go online to view materials, you can also vote your shares.
	Step 1:Go towww.investorvote.com/SLXP.
	Step 2:Click theViewbutton(s) to access the proxy materials.
	Step 3:Return to theinvestorvote.comwindow and follow the instructions on the screen to log in.
	Step 4:Make your selection as instructed on each screen to select delivery preferences and vote.

When you go online, you can also help the environment by consenting to receive electronic delivery of future materials.

Obtaining a copy of the proxy materials – If you want to receive a paper or e-mail copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed on the reverse side on or before June 8, 2009 to facilitate timely delivery.

Annual Stockholder Meeting Notice

The annual meeting of stockholders of Salix Pharmaceuticals, Ltd. will be held on June 18, 2009 at 1700 Perimeter Park Drive, Morrisville, North Carolina, at 9:00 a.m., Eastern Time.

Proposals to be voted on at the annual meeting are listed below along with the Board of Directors’ recommendations.

The Board of Directors recommends that you voteFOR the following proposals:

1. To elect the director nominees listed below until the next annual meeting of stockholders and until their successors are duly elected and qualified:

Nominees: 01 - John F. Chappell, 02 - Thomas W. D’Alonzo, 03 - Richard A. Franco, Sr., 04 - William P. Keane, 05 - Carolyn J. Logan, 06 - Mark A. Sirgo

2. To approve the amendment to Salix Pharmaceuticals, Ltd.’s 2005 Stock Plan to increase the number of shares of common stock reserved for issuance thereunder from 3,900,000 shares to 5,900,000 shares.

3. To ratify the appointment of PricewaterhouseCoopers LLP as Salix Pharmaceuticals, Ltd.’s independent registered public accounting firm for the fiscal year ending December 31, 2009.

4. To consider and act upon on such other matter(s) which may properly come before the annual meeting and at any adjournment(s) thereof.

PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must vote online or request a paper copy of the proxy materials to receive a proxy card. If you wish to attend and vote in person at the annual meeting, please bring a form of photo identification with you.

Directions to the Salix Pharmaceuticals, Ltd. 2009 Annual Meeting

Directions to the annual meeting are available in the proxy statement, which can be viewed atwww.investorvote.com/SLXP.

	Here’s how to order a copy of the proxy materials and select a future delivery preference:
	Paper copies:Current and future paper delivery requests can be submitted via the telephone, Internet or email options below.
	Email copies:Current and future email delivery requests must be submitted via the Internet following the instructions below.
	If you request an email copy of current materials you will receive an email with a link to the materials.
	PLEASE NOTE:You must use the numbers in the shaded bar on the reverse side when requesting a set of proxy materials.
	g	Internet– Go towww.investorvote.com/SLXP.Follow the instructions to log in and order a paper or email copy of the current meeting materials and submit your preference for email or paper delivery of future meeting materials.
	g	Telephone– Call us free of charge at 1-866-641-4276 using a touch-tone phone and follow the instructions to log in and order a paper copy of the materials by mail for the current meeting. You can also submit a preference to receive a paper copy for future meetings.
	g	Email– Send email to investorvote@computershare.com with “Proxy Materials Salix Pharmaceuticals, Ltd.” in the subject line. Include in the message your full name and address, plus the three numbers located in the shaded bar on the reverse, and state in the email that you want a paper copy of current meeting materials. You can also state your preference to receive a paper copy for future meetings.
		To facilitate timely delivery, all requests for a paper copy of the proxy materials must be received by June 8, 2009.
	011OJG